ORIC Pharmaceuticals, Inc.

113 articles about ORIC Pharmaceuticals, Inc.

• ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences - Mar 02, 2021

  3/2/2021

  ORIC Pharmaceuticals, Inc., a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, announced that Jacob Chacko, M.D., chief executive officer, will present a company overview at the following investor conferences in March

• ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences

  2/3/2021

  ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in the following investor conferences in February:

• ORIC Pharmaceuticals Provides Corporate Update and Highlights Key 2021 Milestones

  1/11/2021

  Lead program ORIC-101 continues patient enrollment investigating two therapeutic mechanisms of action and on track for two initial data readouts in 2021

• ORIC Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference

  1/4/2021

  ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that Jacob Chacko, M.D., chief executive officer, will present a company overview at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 12:40 p.m. PT. 

• ORIC Pharmaceuticals Announces Initiation of Expansion Cohorts in Phase 1b Study of ORIC-101

  12/21/2020

  ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the initiation of the Part II dose expansion portion of the Phase 1b study of ORIC-101, a potent and selective glucocorticoid receptor (GR) antagonist, in combination with Abraxane (nab-paclitaxel) for the treatment of advanced solid tumors

• ORIC Pharmaceuticals Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

  11/17/2020

  ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the closing of its previously announced underwritten public offering of 5,796,000 shares of its common stock, which includes the exercise in full of the underwriters’ option to purchase 756,000 additional shares of its common stock,

• ORIC Pharmaceuticals Announces Pricing of Upsized Public Offering - Nov 13, 2020

  11/13/2020

  ORIC Pharmaceuticals, Inc., a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, announced the pricing of an upsized underwritten public offering of 5,040,000 shares of its common stock at a price of $23.00 per share.

• ORIC Pharmaceuticals Announces Proposed Public Offering of Common Stock

  11/10/2020

  ORIC Pharmaceuticals, Inc., a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, announced that it has commenced an underwritten public offering of 4,000,000 shares of its common stock.

• ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences - Nov 09, 2020

  11/9/2020

  ORIC Pharmaceuticals, Inc., a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, announced that Jacob Chacko, M.D., chief executive officer, will participate in the following investor conferences in November:

• ORIC Pharmaceuticals Reports Third Quarter 2020 Financial and Operational Update

  11/5/2020

  Expanded precision oncology pipeline through in-licensing of allostericPRC2 inhibitor program and brain penetrant EGFR and HER2 exon 20 inhibitor program

• ORIC Pharmaceuticals Expands Precision Oncology Pipeline with Exclusive License to Brain Penetrant EGFR/HER2 Exon 20 Inhibitor Program

  10/19/2020

  ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced it has entered into an exclusive license agreement with Voronoi, Inc., an innovative drug discovery company dedicated to advancing novel therapeutics

• ORIC Pharmaceuticals Announces Presentation of Preclinical Data on Glucocorticoid Receptor Antagonist Overcoming Resistance to an Androgen Receptor Degrader at the 32nd EORTC-NCI-AACR Symposium 2020

  10/9/2020

  ORIC Pharmaceuticals, Inc. announced a poster presentation and oral discussion at the upcoming 32nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics being held virtually October 24 - 25, 2020.

• ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences - Sep 02, 2020

  9/2/2020

  ORIC Pharmaceuticals, Inc., a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, announced that Jacob Chacko, M.D., chief executive officer, will participate in the following investor conferences in September:

• ORIC Pharmaceuticals Reports Second Quarter 2020 Financial and Operational Update

  8/5/2020

  ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today reported financial results for the quarter ended June 30, 2020.

• ORIC Pharmaceuticals Expands Precision Oncology Pipeline with Exclusive Worldwide License to Highly Selective Allosteric PRC2 Inhibitors from Mirati Therapeutics

  8/5/2020

  ORIC licenses exclusive worldwide development and commercialization rights to a potential best-in-class PRC2 inhibitor

• ORIC Pharmaceuticals to Host Second Quarter 2020 Financial Results Conference Call

  8/4/2020

  ORIC Pharmaceuticals, Inc., a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, announced that management will host a conference call and webcast to discuss its second quarter 2020 financial results and other business highlights on Wednesday, August 5, 2020, at 4:30 p.m. ET.

• ORIC Pharmaceuticals Presents Preclinical Data on Glucocorticoid Receptor Antagonist and CD73 Inhibitor Programs at the 2020 American Association for Cancer Research Virtual Annual Meeting II

  6/22/2020

  ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today presented preclinical data from the company’s glucocorticoid receptor (GR) antagonist and CD73 inhibitor programs in five poster presentations during the ongoing American Association for Cancer Research (AACR) Virtual Annual Meeting II. “We are pleased to be

• ORIC Pharmaceuticals Appoints Lori Kunkel, M.D., to its Board of Directors

  6/9/2020

  ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the appointment of Lori Kunkel, M.D., to its board of directors

• ORIC Pharmaceuticals Announces Five Presentations at the 2020 American Association for Cancer Research Virtual Annual Meeting II

  5/27/2020

  ORIC Pharmaceuticals, Inc. announced that multiple poster presentations highlighting preclinical data from the company’s glucocorticoid receptor antagonist and CD73 inhibitor programs will be presented at the upcoming American Association for Cancer Research Virtual Annual Meeting II being held June 22-24, 2020.

• ORIC Pharmaceuticals to Present at the Jefferies 2020 Global Healthcare Conference

  5/26/2020

  ORIC Pharmaceuticals, Inc., a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, announced that Jacob Chacko, M.D., chief executive officer, will present a company overview at the Jefferies Virtual Healthcare Conference on Tuesday, June 2, 2020, at 11:00 am ET.